$ASMB Cashflow Statement | Understand Stock

$ASMB

$20.30 +$0.00 (0.0%) After hours

$ASMB Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment of goodwill and indefinite-lived intangible asset
Depreciation and amortization
Non-cash in-process research and development (IPR&D) expense
Stock-based compensation
Net accretion and amortization of investments in marketable debt securities
Net amortization of investments in marketable debt securities
Net accretion of investments in marketable debt securities
Non-cash rent expense
Deferred income tax expense
Loss on disposal of property and equipment
Gain on the sale of Microbiome assets
Realized gain on investments in marketable debt securities
Changes in operating assets and liabilities:
Accounts receivable from collaboration
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued research and development expenses
Other accrued expenses
Deferred revenue from a related party
Operating lease liabilities

Net cash used in operating activities
Cash flows from investing activities
Proceeds from maturities of marketable securities
Purchases of marketable securities
Proceeds from sale of property and equipment
Purchase of IPR&D from an acquisition of assets
Purchases of property and equipment
Proceeds from sale of marketable securities
Proceeds from the sale of Microbiome assets
Net cash (used in) provided by investing activities

Cash flows from financing activities
Proceeds from the issuance of common stock to a related party, net of issuance costs
Proceeds from the issuance of common stock, pre-funded warrants and warrants in an underwritten offering, net of issuance costs
Proceeds from the issuance of common stock and warrants in private placements to a related party, net of issuance costs
Proceeds from the exercise of warrants
Proceeds from the issuance of common stock under ATM equity offering program, net of issuance costs
Proceeds from the issuance of common stock under ESPP
Proceeds from the exercise of stock options
Proceeds from the issuance of common stock and warrants in a registered direct offering, net of issuance costs
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
Supplemental non-cash investing and financing activities
Operating lease liabilities arising from obtaining ROU assets
Remeasurement of lease liabilities arising from modification of ROU assets
Receivable from sale of Microbiome assets included in prepaid expenses and other current assets

Income taxes paid

Comments